期刊文献+

肺表面活性物质联合布地奈德预防极低出生体重儿支气管肺发育不良的疗效观察 被引量:50

Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants
原文传递
导出
摘要 目的探讨肺表面活性物质(PS)联合布地奈德气管内滴入预防极低出生体重早产儿支气管肺发育不良(BPD)的临床疗效。方法选取胎龄<32周的患有宫内感染的呼吸窘迫综合征(NRDS)(Ⅲ或Ⅳ级)的极低出生体重儿30例,随机分成PS+布地奈德组(15例)和PS组(15例)。比较两组血气分析、氧合指数(OI)、呼吸机使用时间、吸氧时间、BPD发生率、纠正胎龄36周时病死率以及其他并发症的发生率。结果 PS+布地奈德组患儿BPD发生率低于PS组,呼吸机使用时间和吸氧时间明显短于PS组(P<0.05);给药后第2~6天,PS+布地奈德组pH、OI均高于PS组,PaCO——2均低于PS组,且差异均有统计学意义(P<0.05);两组间纠正胎龄36周时病死率以及其他并发症差异无统计学意义。结论 PS联合布地奈德气管内滴入能有效降低重度NRDS极低出生体重早产儿BPD的发生率。 Objective To explore the clinical efficacy of intratracheal instillation of pulmonary surfactant(PS) combined with budesonide for preventing bronchopulmonary dysplasia(BPD) in very low birth weight(VLBW) infants. Methods Thirty VLBW infants with gestational age〈 32 weeks who developed neonatal respiratory distress syndrome(NRDS)(grade III-IV) suffering from intrauterine infection were randomly assigned into a PS + budesonide group and a PS alone group. The changes were compared between the two groups in arterial blood gas indexes, oxygenation index(OI), duration of mechanical ventilation, duration of oxygen supplementation, incidence of BPD, mortality rate at 36 weeks corrected gestational age and incidences of other complications except BPD. Results Compared with the PS alone group, the PS+budesonide group had a lower incidence of BPD, shorter duration of mechanical ventilation and oxygen supplementation(P〈0.05). On the 2nd to 6th day after treatment, the PS+budesonide group had higher p H value of arterial blood gas and OI and lower carbon dioxide partial pressure compared with the PS alone group(P〈0.05). There were no significant differences in the mortality rate at 36 weeks corrected gestational age and the incidences of other complications except BPD between the two groups(P〉0.05). Conclusions Intratracheal instillation of PS combined with budesonide can effectively reduce the incidence of BPD in VLBW premature infants with severe NRDS.
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2017年第2期137-141,共5页 Chinese Journal of Contemporary Pediatrics
基金 安徽省自然科学基金项目(No.1608085MH196) 中华儿科杂志珂立苏儿科科研基金项目资助
关键词 布地奈德 肺表面活性物质 支气管肺发育不良 极低出生体重儿 Budesonide Pulmonary surfactant Bronchopulmonary dysplasia Very low birth weight infant
  • 相关文献

参考文献3

二级参考文献83

  • 1陈幽,韩玉昆,叶贞志,卢光进.呼吸窘迫综合征并发支气管肺发育不良危险因素分析[J].中国当代儿科杂志,2007,9(1):15-18. 被引量:14
  • 2Hazinski TA.Drug treatment for established BPD.In:Bland RD,Coalson J J,eds.Chronic lung disease in early infancy.New York:Marcel Dekker; 2000:257-283.
  • 3Bland RD,Coalson J.Chronic lung disease in early infancy.New York:Marcel Dekker; 2000:237.
  • 4Jobe AH,Bancalari E.Bronchopulmonary dysplasia.Am J Respir Crit Care Med 2001; 163:1723-1729.
  • 5Walsh MC,Yao Q,Gettner P,Hale E,Collins M,Hensman A,et al.Impact of a physiologic definition on bronchopulmonary dysplasia rates.Pediatrics 2004; 114:1305-1311.
  • 6Ballard RA,Truog WE,Cnaan A,Martin R J,Ballard PL,Merrill JD,et al.Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.N Engl J Med 2006; 355:343-353.
  • 7Tin W,Wiswell TE.Adjunctive therapies in chronic lung disease:Examining the evidence.Semin Fetal Neonat Med 2008; 13:44-52.
  • 8Barrington KJ.The adverse neuro-developmental effects of postnatal steroids in the preterm infant:a systematic review of RCTs.BMC Pediatr 2001; 1:1.
  • 9Shinwell ES.Current dilemmas in postnatal steroid therapy for chronic lung disease in preterm infants.Biol Neonate 2003; 84:96-100.
  • 10Sweet DG,Halliday HL.A risk benefit assessment of drugs used for neonatal chronic lung disease.Drug Safety 2000; 22:389-404.

共引文献42

同被引文献366

引证文献50

二级引证文献374

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部